Details
Description
This analysis investigates the risk of severe uterine bleed for patients treated with Novel Oral Anticoagulants (NOACs) (including Rivaroxaban, Dabigatran, Apixaban), and Warfarin in the Sentinel Distributed Database. This request includes two reports:
- Report 1: This request was distributed to Data Partners on October 11, 2017.
- Report 2: This analysis is an update to the previous request, including new indication covariates, redefined age groups, and revisions to the propensity score stratification analysis. This request was distributed to Data Partners on December 30, 2019.
The analytic packages associated with this analysis can be found externally in Sentinel's Git Repository located here: Package 1, Package 2. The Git Repository serves as Sentinel's version control tracking system for analytic packages and technical documentation.
Deliverables (4)
Sentinel Modular Program Report: Severe Uterine Bleed Following Novel Oral Anticoagulants Use: A Propensity Score Matched Analysis, Report 1
Sentinel Modular Program Report: Severe Uterine Bleed Following Novel Oral Anticoagulants Use: A Propensity Score Stratified Analysis, Report 2
Sentinel Analytic Package: Severe Uterine Bleed Following Novel Oral Anticoagulants Use: A Propensity Score Analysis, Package 1
Sentinel Analytic Package: Severe Uterine Bleed Following Novel Oral Anticoagulants Use: A Propensity Score Analysis, Package 2